Sales & Marketing Four reasons pharma is sweeping the Super Bowl despite FDA f... The FDA has signalled increased scrutiny of D2C pharma advertising. So why is pharma stepping up its advertising at Super Bowl LX?
Sales & Marketing 5 takeaways from Super Bowl LIX: What health and pharma can ... Super Bowl advertising has always been about pushing boundaries, capturing attention, and setting new creative standards. But this year, the risk-taking was noticeably dialled down.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.